AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2510877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and verapamil (25 mg and 240 mg)
Number of subjects: 369
Study 2510877 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen V (combination treatment)
Number of subjects: 369
Study 2510877 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 369
Study 2510877 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 369
Study 2510877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining verapamil with hydrochlorothiazide
Number of subjects: 369
Study 2510877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining hydrochlorothiazide with verapamil
Number of subjects: 369
Study 4417365 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymous group administered questionnaires
Number of subjects: 66
Study 4417365 — intervention group
Group type: EXPERIMENTAL
Intervention: Anonymous interviews
Number of subjects: 66
Study 4417365 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviews with subject's name verified at the outset
Number of subjects: 66
Study 4417365 — intervention group
Group type: COMPARATOR
Intervention: All assessment conditions
Number of subjects: 66
Study 31623758 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy (DAPT) followed by 23-month ticagrelor monotherapy
Number of subjects: 3576
Study 31623758 — intervention group
Group type: COMPARATOR
Intervention: 12-month DAPT followed by 12-month aspirin monotherapy
Number of subjects: 3576
Study 26773736 — intervention group
Group type: EXPERIMENTAL
Intervention: Curved abutment design (experimental)
Number of subjects: 26
Study 26773736 — intervention group
Group type: COMPARATOR
Intervention: Divergent abutment design (control)
Number of subjects: 26
Study 26773736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both abutment designs (Curved and Divergent)
Number of subjects: 26
Study 24357450 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial endoscopic perforating vein surgery (SEPS) with ambulatory compression therapy
Number of subjects: 94
Study 24357450 — intervention group
Group type: COMPARATOR
Intervention: Incomplete SEPS procedure
Number of subjects: 94
Study 24357450 — intervention group
Group type: COMPARATOR
Intervention: New incompetent perforating veins
Number of subjects: 94
Study 24357450 — intervention group
Group type: COMPARATOR
Intervention: Deep vein incompetence and treatment of superficial venous incompetence
Number of subjects: 94
Study 24922652 — intervention group
Group type: EXPERIMENTAL
Intervention: HyperBaric Oxygen (HBO) session the day before intervention (group A)
Number of subjects: 21
Study 24922652 — intervention group
Group type: COMPARATOR
Intervention: Air breathing for 40 min in a hyperbaric chamber (placebo group, group B)
Number of subjects: 21
Study 22317061 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay@Work Participatory Ergonomics programme (PE)
Number of subjects: 3047
Study 22317061 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PE)
Number of subjects: 3047
Study 19048230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 0
Study 19048230 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17296414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 369
Study 17296414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 369
Study 15896236 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of itraconazole alone
Number of subjects: 12
Study 15896236 — intervention group
Group type: COMPARATOR
Intervention: 200 mg of itraconazole co-administered with antacid suspension
Number of subjects: 12
Study 11971884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention aimed at clinicians to improve patient health
Number of subjects: 0
Study 11971884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster-randomized trials
Number of subjects: 0
Study 11971884 — intervention group
Group type: COMPARATOR
Intervention: Individual-randomized trials
Number of subjects: 0
Study 9708455 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (ReoPro, c7E3 Fab) bolus plus 12-hour infusion
Number of subjects: 2099
Study 9708455 — intervention group
Group type: COMPARATOR
Intervention: abciximab (ReoPro, c7E3 Fab) bolus only
Number of subjects: 2099
Study 9708455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2099
Study 9708455 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (ReoPro, c7E3 Fab)
Number of subjects: 2099
Study 9708455 — intervention group
Group type: EXPERIMENTAL
Intervention: bolus-plus-infusion treatment
Number of subjects: 2099
Study 7634747 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic exercise
Number of subjects: 26
Study 7634747 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial occlusion
Number of subjects: 26
Study 2694463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine plus sulfadoxine‐pyrimethamine (MSP)
Number of subjects: 193
Study 2694463 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine (SP)
Number of subjects: 193
Study 354732 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment (pimozide)
Number of subjects: 31
Study 354732 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment (fluphenazine)
Number of subjects: 31
Study 354732 — intervention group
Group type: COMPARATOR
Intervention: Drug-free schizophrenic patients
Number of subjects: 31
Study 354732 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who remitted after neuroleptic withdrawal
Number of subjects: 31
Study 354732 — intervention group
Group type: EXPERIMENTAL
Intervention: Catatonic schizophrenic patients
Number of subjects: 31
Study 31699604 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention for refugees (FSI-R)
Number of subjects: 40
Study 31699604 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 40
Study 30045592 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal RF; thermal RF neurolysis was applied with a time of 60 seconds at 80º C, repeated twice after needle-tip rotation.
Number of subjects: 80
Study 30045592 — intervention group
Group type: COMPARATOR
Intervention: Pulsed RF; super voltage pulsed RF was applied with a time of 360 seconds at 42º C, with a pulse width of 20 m/sec and voltage of 60‐70 v.
Number of subjects: 80
Study 26323328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intervention (details not specified)
Number of subjects: 338
Study 25573317 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% H2 inhalation for 1 h at 1 h and 6 h after CLP operation
Number of subjects: 84
Study 25573317 — intervention group
Group type: COMPARATOR
Intervention: Sepsis group (control)
Number of subjects: 84
Study 22537766 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT)
Number of subjects: 20
Study 22537766 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 20
Study 20191522 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 0
Study 20191522 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 0
Study 18823458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate (RL) solution
Number of subjects: 44
Study 18823458 — intervention group
Group type: COMPARATOR
Intervention: Gelatin-containing solution
Number of subjects: 44
Study 16077392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 100 mg/kg
Number of subjects: 312
Study 16077392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 12623505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-methotrexate chemotherapy (3 courses)
Number of subjects: 317
Study 12623505 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment (control group)
Number of subjects: 317
Study 10349036 — intervention group
Group type: EXPERIMENTAL
Intervention: D,L-fenfluramine (FEN) 60 mg oral dose
Number of subjects: 38
Study 10349036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8951631 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/copolymer toothpaste
Number of subjects: 129
Study 8951631 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoride toothpastes (including a children's fluoride toothpaste)
Number of subjects: 129
Study 1958601 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ml 0.5% bupivacaine with 5 micrograms/ml epinephrine
Number of subjects: 10
Study 1958601 — intervention group
Group type: COMPARATOR
Intervention: 20 ml 0.5% bupivacaine without epinephrine
Number of subjects: 10
Study 1958601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (bupivacaine with and without epinephrine)
Number of subjects: 10
Study 7128675 — intervention group
Group type: EXPERIMENTAL
Intervention: PB-sodium 130 mg i.v. (IV)
Number of subjects: 12
Study 7128675 — intervention group
Group type: EXPERIMENTAL
Intervention: PB sodium 10 mg i.m. (IM)
Number of subjects: 12
Study 7128675 — intervention group
Group type: EXPERIMENTAL
Intervention: PB acid 100 mg orally (PO)
Number of subjects: 12
Study 7128675 — intervention group
Group type: EXPERIMENTAL
Intervention: Epileptic patients (treated with phenytoin or carbamazepine)
Number of subjects: 12
Study 31154591 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of patients' religious beliefs in RCTs related to bone grafting procedures
Number of subjects: 0
Study 30721294 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-guided treat-to-target strategy
Number of subjects: 200
Study 30721294 — intervention group
Group type: COMPARATOR
Intervention: Conventional treat-to-target strategy
Number of subjects: 200
Study 28196467 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation letter to participate in screening (IG1)
Number of subjects: 15965
Study 28196467 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation letter and informative leaflet (IG2)
Number of subjects: 15965
Study 28196467 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation letter, informative leaflet, and phone call reminder (IG3)
Number of subjects: 15965
Study 28196467 — intervention group
Group type: COMPARATOR
Intervention: No intervention group (NIG)
Number of subjects: 15965
Study 24575793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential erlotinib (150 mg/day on day 15 through day 28) and gemcitabine (1250 mg/m2 Day 1, 8 q28 days)
Number of subjects: 54
Study 24575793 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (1000 mg/m2 Days 1, 8, 15 q28 days)
Number of subjects: 54
Study 24575793 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential erlotinib and gemcitabine (EG-arm)
Number of subjects: 54
Study 24575793 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine monotherapy (G-arm)
Number of subjects: 54
Study 25070687 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus
Number of subjects: 300
Study 25070687 — intervention group
Group type: COMPARATOR
Intervention: cyclosporine
Number of subjects: 300
Study 22357185 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 390
Study 22357185 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IG)
Number of subjects: 390
Study 19095219 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine treatment
Number of subjects: 250
Study 17898508 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple polyphenols (600 mg/day for 12 weeks)
Number of subjects: 71
Study 17898508 — intervention group
Group type: COMPARATOR
Intervention: Hop bract polyphenol-containing capsules (600 mg/day for 12 weeks)
Number of subjects: 71
Study 14986055 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine/left decubitus scanning
Number of subjects: 50
Study 14986055 — intervention group
Group type: COMPARATOR
Intervention: Supine/prone scanning
Number of subjects: 50
Study 11602484 — intervention group
Group type: EXPERIMENTAL
Intervention: Behçet's syndrome with arthritis
Number of subjects: 44
Study 11602484 — intervention group
Group type: COMPARATOR
Intervention: Behçet's syndrome without arthritis
Number of subjects: 44
Study 11602484 — intervention group
Group type: COMPARATOR
Intervention: Active rheumatoid arthritis
Number of subjects: 44
Study 11602484 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 44
Study 9602763 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg, 3 times per day for 8 days
Number of subjects: 209
Study 9602763 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg, 3 times per day for 4 days
Number of subjects: 209
Study 8137332 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinoid isotretinoin
Number of subjects: 0
Study 3344690 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing instruction and support through 10 staff-initiated telephone contacts of 5 minutes each every 2 weeks
Number of subjects: 103
Study 3344690 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-monitoring and adherence instructions
Number of subjects: 103
Study 3344690 — intervention group
Group type: COMPARATOR
Intervention: Weekly self-monitoring only
Number of subjects: 103
Study 31899001 — intervention group
Group type: EXPERIMENTAL
Intervention: HDA-R (high-disease-activity relapsing)
Number of subjects: 6647
Study 31899001 — intervention group
Group type: EXPERIMENTAL
Intervention: HDA-L (high-disease-activity lesion)
Number of subjects: 6647
Study 31899001 — intervention group
Group type: COMPARATOR
Intervention: LDA (low-disease-activity)
Number of subjects: 6647
Study 31563387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle eversion taping
Number of subjects: 15
Study 31563387 — intervention group
Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 15
Study 31563387 — intervention group
Group type: COMPARATOR
Intervention: No taping
Number of subjects: 15
Study 28425778 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation Awareness Training (MAT)
Number of subjects: 73
Study 28425778 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 73
Study 26162281 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Adaptation Skills Training (LAST) program, 24 sessions, plus 24 phone contacts for support
Number of subjects: 68
Study 26162281 — intervention group
Group type: COMPARATOR
Intervention: Control group (phone contact only, 24 times)
Number of subjects: 68
Study 24266074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral canal injection
Number of subjects: 65
Study 24266074 — intervention group
Group type: COMPARATOR
Intervention: Lumbar oblique wrench
Number of subjects: 65
Study 16817651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense anxiety response during flying
Number of subjects: 28
Study 16817651 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate excitement response during flying
Number of subjects: 28
Study 16817651 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 28
Study 16817651 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 28
Study 16817651 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and excitement
Number of subjects: 28
Study 14521170 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin regimen with pre‐breakfast injections
Number of subjects: 16
Study 14521170 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin regimen with pre‐dinner injections
Number of subjects: 16
Study 14521170 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin regimen with bedtime injections
Number of subjects: 16
Study 14521170 — intervention group
Group type: COMPARATOR
Intervention: Overall quality of glycemic control (HbAIC) for different regimens
Number of subjects: 16
Study 10561203 — intervention group
Group type: EXPERIMENTAL
Intervention: Formestane (250 mg intramuscularly biweekly)
Number of subjects: 128
Study 10561203 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate (160 mg orally daily)
Number of subjects: 128
Study 8554206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy with sulfonylurea
Number of subjects: 4209
Study 8554206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy with insulin
Number of subjects: 4209
Study 8554206 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (diet alone)
Number of subjects: 4209
Study 8554206 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 4209
Study 1649683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus Vindesine (CDDP + VDS)
Number of subjects: 160
Study 1649683 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP) alone
Number of subjects: 160
Study 6347243 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 117
Study 6347243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 30736083 — intervention group
Group type: EXPERIMENTAL
Intervention: Malagueta (30 CH)
Number of subjects: 40
Study 30736083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28421205 — intervention group
Group type: EXPERIMENTAL
Intervention: 470 nm light
Number of subjects: 103
Study 28421205 — intervention group
Group type: EXPERIMENTAL
Intervention: 635 nm light
Number of subjects: 103
Study 28421205 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue light stimulation
Number of subjects: 103
Study 25724655 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 0
Study 25724655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25724655 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 0
Study 23903090 — intervention group
Group type: EXPERIMENTAL
Intervention: Active microcurrent with silver-coated nylon dressing
Number of subjects: 30
Study 23903090 — intervention group
Group type: COMPARATOR
Intervention: Sham microcurrent with silver-coated nylon dressing
Number of subjects: 30
Study 21706526 — intervention group
Group type: EXPERIMENTAL
Intervention: BSF+ (ongoing MI training with audio-recorded feedback in peer groups)
Number of subjects: 45
Study 21706526 — intervention group
Group type: COMPARATOR
Intervention: BSF (workshop-only MI training)
Number of subjects: 45
Study 21706526 — intervention group
Group type: COMPARATOR
Intervention: UPI (usual prison planning interviews)
Number of subjects: 45
Study 19466447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowlanders tested at sea level (LL-SL)
Number of subjects: 90
Study 19466447 — intervention group
Group type: EXPERIMENTAL
Intervention: Native highlanders tested at altitude (HAN)
Number of subjects: 90
Study 19466447 — intervention group
Group type: COMPARATOR
Intervention: Lowlanders tested at altitude (LL-HA)
Number of subjects: 90
Study 16715913 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylergometrine 0.2 mg bolus (MEM group; n = 34)
Number of subjects: 136
Study 16715913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 10 IU over 30 seconds (OX 30 s group; n = 34)
Number of subjects: 136
Study 16715913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 10 IU over 5 minutes (OX 5 m group; n = 34)
Number of subjects: 136
Study 16715913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin 10 IU over 15 minutes (OX 15 m group; n = 34)
Number of subjects: 136
Study 15477411 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/d during the open-label period
Number of subjects: 15432
Study 15477411 — intervention group
Group type: COMPARATOR
Intervention: Drug-washout period (no statin therapy)
Number of subjects: 15432
Study 11156874 — intervention group
Group type: EXPERIMENTAL
Intervention: Hirudin
Number of subjects: 0
Study 11156874 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 11156874 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Hirudin and Unfractionated heparin)
Number of subjects: 0
Study 9158354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.3 ng/ml)
Number of subjects: 49
Study 9158354 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.6 ng/ml)
Number of subjects: 49
Study 9158354 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 49
Study 7967730 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside (3 g/m2 every 12 h for 6 days) with etoposide (100 mg/m2 days 7-9)
Number of subjects: 131
Study 7967730 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytosine arabinoside (3 g/m2 every 12 h for 6 days) alone
Number of subjects: 131
Study 7967730 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen (high-dose cytosine arabinoside with etoposide)
Number of subjects: 131
Study 7967730 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 131
Study 7967730 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year disease-free survival
Number of subjects: 131
Study 3310634 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 2 g per day
Number of subjects: 71
Study 3310634 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg per day
Number of subjects: 71
Study 29534975 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS) to the left DLPFC
Number of subjects: 32
Study 29534975 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS) to the left DLPFC
Number of subjects: 32
Study 28245852 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse shoulder arthroplasty
Number of subjects: 0
Study 28245852 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 0
Study 25636672 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative embolization
Number of subjects: 45
Study 25636672 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 25636672 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative embolization (hypervascular metastases)
Number of subjects: 45
Study 25636672 — intervention group
Group type: COMPARATOR
Intervention: Control group (hypervascular metastases)
Number of subjects: 45
Study 23656351 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose L-arginine (6 g/day for at least 24 months)
Number of subjects: 4